The specter of head impact trauma is real for every parent of every kid who regularly collides with others on playing fields. Active adults don’t get a pass from concerns about head injuries that could result in concussions, either. We’ve written about several technologies that assess brain injuries ranging from optical tracking to blood tests.
We first wrote about Oculogica’s EyeBox in 2020. The FDA cleared the EyeBox to help diagnose concussions in patients 5 through 67 years old. FDA clearance followed a published study that showed the EyeBox could return results within minutes that compared well with gold standard Acute Concussion Evaluation (ACE) scores. ACE testing entails clinical judgment based on patient observation, patient history, and current symptoms. The EyeBox doesn’t require knowledge of patient symptoms or history. This means that you don’t have to have a baseline measurement on record. With its AI-driven software, the EyeBox can also help locate the injury by analyzing cranial nerve group performance.
Oculogica recently announced FDA clearance for its latest generation EyeBox. The newest model has the same capabilities as the previous generation but in a lighter, more compact size: small enough to carry in a backpack, according to an Oculogica news release. Speaking about the newest generation device, Oculogica’s CEO, Rosina Samadini, PhD, said, “The new lightweight form factor allows it to be easily transported. Concussions happen everywhere and our latest device was designed with that in mind. We have now received 4 clearances from [the] FDA since 2019, which is more than any other baseline-free concussion assessment in the industry.”
The latest EyeBox runs on batteries and weighs just 11 pounds. In less than four minutes the noninvasive EyeBox test can diagnosis head impacts objectively in both adults and children. Faster diagnosis or clearance allows faster treatment when appropriate as well as sending players back on the field or back to work when that’s okay, too.
